Literature DB >> 6084222

Natural history of choroidal neovascularization in degenerative myopia.

M P Avila, J J Weiter, A E Jalkh, C L Trempe, R C Pruett, C L Schepens.   

Abstract

We studied 354 eyes with myopic chorioretinal degeneration by means of standard clinical evaluation and fluorescein angiography. The eyes were classified on the basis of the degree of chorioretinal degeneration found in the posterior pole. Lacquer cracks (breaks in Bruch's membrane) were noted in 82% of the 149 eyes with choroidal neovascular membranes (CNM) and in 96% of the 58 eyes with isolated subretinal hemorrhages. These hemorrhages were reabsorbed without adverse visual sequelae in 32 eyes that were followed; in 14 of these eyes that were followed closely, the average time of reabsorption was 6.4 weeks. Seventy eyes with CNM were followed for an average of 40.9 months. In 96% of these eyes the CNM remained stable or regressed, leaving an atrophic, nonexudative scar. This study indicates that CNM in degenerative myopia is usually self-limited.

Entities:  

Mesh:

Year:  1984        PMID: 6084222     DOI: 10.1016/s0161-6420(84)34116-1

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  84 in total

1.  Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients.

Authors:  J M Ruiz-Moreno; C de la Vega
Journal:  Br J Ophthalmol       Date:  2001-09       Impact factor: 4.638

2.  Myopia in Singapore: taking a public health approach.

Authors:  B Seet; T Y Wong; D T Tan; S M Saw; V Balakrishnan; L K Lee; A S Lim
Journal:  Br J Ophthalmol       Date:  2001-05       Impact factor: 4.638

3.  Visual outcomes for high myopic patients with or without myopic maculopathy: a 10 year follow up study.

Authors:  Y-F Shih; T-C Ho; C K Hsiao; L L-K Lin
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

4.  Spectral-domain OCT in anti-VEGF treatment of myopic choroidal neovascularization.

Authors:  U Introini; G Casalino; G Querques; A T Gimeno; F Scotti; F Bandello
Journal:  Eye (Lond)       Date:  2012-04-27       Impact factor: 3.775

5.  Outcome of photodynamic therapy in choroidal neovascularization due to pathologic myopia and related factors.

Authors:  Tugrul Altan; Nur Acar; Ziya Kapran; Yaprak B Unver; Sezin Ozdogan
Journal:  Int Ophthalmol       Date:  2012-02-19       Impact factor: 2.031

6.  The 12-month outcome of three consecutive monthly intravitreal injections of ranibizumab for myopic choroidal neovascularization.

Authors:  Tsung-Tien Wu; Ya-Hsin Kung
Journal:  J Ocul Pharmacol Ther       Date:  2011-11-08       Impact factor: 2.671

7.  Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.

Authors:  T Y Y Lai; F O J Luk; G K Y Lee; D S C Lam
Journal:  Eye (Lond)       Date:  2012-05-18       Impact factor: 3.775

Review 8.  Choroidal neovascularisation in pathological myopia: an update in management.

Authors:  W-M Chan; M Ohji; T Y Y Lai; D T L Liu; Y Tano; D S C Lam
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

9.  Dissecting the genetics of human high myopia: a molecular biologic approach.

Authors:  Terri L Young
Journal:  Trans Am Ophthalmol Soc       Date:  2004

10.  Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation in pathologic myopia.

Authors:  Faik Gelisken; Werner Inhoffen; Alexander Hermann; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-07-17       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.